Nurix Therapeutics (NRIX) Equity Average (2019 - 2025)
Historic Equity Average for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $455.5 million.
- Nurix Therapeutics' Equity Average rose 79.11% to $455.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $455.5 million, marking a year-over-year increase of 79.11%. This contributed to the annual value of $532.9 million for FY2025, which is 4649.63% up from last year.
- Nurix Therapeutics' Equity Average amounted to $455.5 million in Q4 2025, which was up 79.11% from $409.9 million recorded in Q3 2025.
- Over the past 5 years, Nurix Therapeutics' Equity Average peaked at $504.0 million during Q1 2025, and registered a low of $184.6 million during Q1 2024.
- For the 5-year period, Nurix Therapeutics' Equity Average averaged around $336.6 million, with its median value being $323.6 million (2022).
- Its Equity Average has fluctuated over the past 5 years, first tumbled by 3608.96% in 2024, then soared by 17296.81% in 2025.
- Over the past 5 years, Nurix Therapeutics' Equity Average (Quarter) stood at $358.8 million in 2021, then decreased by 9.93% to $323.1 million in 2022, then tumbled by 32.79% to $217.2 million in 2023, then soared by 108.11% to $451.9 million in 2024, then grew by 0.79% to $455.5 million in 2025.
- Its Equity Average was $455.5 million in Q4 2025, compared to $409.9 million in Q3 2025 and $464.3 million in Q2 2025.